산업화된 현대 흙건축 자재를 위한 표준시험법 고찰 및 제안

이은주(Eunjoo Lee),권오진(Ojin Kwon) 한국생태환경건축학회 2022 한국생태환경건축학회 논문집 Vol.22 No.6

Effect of herbal medicine (Huanglian-jie-du granule) for somatic symptoms and insomnia in patients with Hwa-byung: A randomized controlled trial

최유진,Yunna Kim,Ojin Kwon,Sun-Yong Chung,조성훈 한국한의학연구원 2021 Integrative Medicine Research Vol.10 No.2

Background: Huanglian-jie-du (HJD) granule, which is composed of representative “heat-clearing” herbs has been used for Hwa-byung. Hwa-byung is a culture-bound syndrome in Korea, characterized by distinct somatic symptoms such as chest congestion and heat sensation resulting from suppressed anger. We investigated the effect of HJD in patients with Hwa-byung. Methods: Forty-four patients with Hwa-byung were recruited, and HJD or placebo granules were administered orally three times daily for seven days. The two primary outcomes were somatic symptoms, which were measured by Patient Health Questionnaire of physical symptoms (PHQ-15), and insomnia, which was measured by Insomnia Severity Index (ISI) at post-treatment. Results: Between July 10 and October 31, 2017, 44 patients with Hwa-byung (mean age 36.68 years; and 38 female) were randomly assigned to HJD (n = 22) or placebo (n = 22) group. After administration of HJD or placebo granule for seven days, ISI score was lower in the HJD group compared to placebo group at post-treatment (adjusted mean difference -2.56 [95% CI -4.72 to -0.39], p = 0.0208). Meanwhile, there was no difference in PHQ-15 score between HJD group and placebo group at post-treatment (adjusted mean difference -0.50 [95% CI: -3.02–4.02], p = 0.7812). Conclusions: Our results suggest that the administration of HJD granule has a potential to improve insomnia in Hwa-byung patients. Effect of HJD granule for general somatic symptoms in Hwa-byung patients is unclear, and further researches are needed.

Electroacupuncture plus moxibustion for major depressive disorder: A randomized, sham-controlled, pilot clinical trial

김미경,Eun-Ji Choi,Ojin Kwon,Hyo-ju Park,Ae-Ran Kim,Bok-Nam Seo,Sun-Yong Chung,이준환,김주희 한국한의학연구원 2021 Integrative Medicine Research Vol.10 No.3

Background: The first treatment option for major depressive disorder (MDD) is antidepressants, however, there is substantial demand for alternative therapies due to its low compliance and remission rates. This study was aimed to explore the effectiveness, safety, and feasibility of electroacupuncture plus moxibustion therapy for MDD. Methods: Thirty adults with MDD were randomly assigned to the treatment group (TG) or control group (CG). The TG was treated with electroacupuncture plus moxibustion, and the CG received sham interventions at non-acupoints for 8 weeks. The primary outcome measure was the intergroup difference of the mean change of total score of the Hamilton rating scale for depression (HRSD) between baseline and week 9. Secondary outcome measures were Beck's depression inventory, insomnia severity index, the state-trait anxiety inventory, the EuroQol-5 dimension index, the measure yourself medical outcome profile version 2, and frontal alpha asymmetry measured by electroencephalography. Adverse events (AEs) were monitored for safety assessment. Results: The primary outcome measure was not significantly different between the two groups (p=0.2641), although the scores of HRSD in both groups improved significantly after treatment. No significant difference was identified between groups in secondary outcome measures. The incidence of AE was not significantly different between the two groups (p=0.1067). Conclusion: A clinical trial using electroacupuncture plus moxibustion for MDD seems feasible. However, further studies with the larger size, adopting ideal controls are warranted to provide a confirmative conclusion to the efficacy and safety of electroacupuncture plus moxibustion for MDD.

Lowering the potential barrier of a bistable energy harvester with mechanically rectified motion of an auxiliary magnet oscillator

Nguyen, Minh Sang,Yoon, Yong-Jin,Kwon, Ojin,Kim, Pilkee American Institute of Physics 2017 Applied Physics Letters Vol.111 No.25

고도비만 환자 대상 한의 비만 상담을 포함한 한의치료의 체중 감량 효과 : 후향적 차트 리뷰

김성하(Sungha Kim),한경선(Kyungsun Han),권오진(Ojin Kwon),이원구(Wongu Lee),윤철상(Chulsang Yoon),이준환(Jun-Hwan Lee) 한방비만학회 2021 한방비만학회지 Vol.21 No.1

Objectives: We conducted a retrospective chart review to investigate the effects of Korean Medicine (KM) treatment on weight loss in patients with morbid obesity (body mass index [BMI]≥30 kg/m2) and to compare the effects of KM counseling and non-counseling on weight loss. Methods: We performed a retrospective chart review of patients with morbid obesity who received KM treatment for at least 1 month. We evaluated the effects of KM treatment on body weight, BMI, body fat, fat mass, EuroQol-5D, and the Korean version of the obesity-related quality of life scale (KOQOL). We also assessed the liver and kidney functions, and adverse events. We performed a comparative analysis between the counseling and non-counseling groups. Results: A total of 37 patients who underwent 4 weeks of KM treatment involving Wolbi-tang, electroacupuncture, and KM counseling were included in this study. Twenty-one patients were assigned to the counseling group and sixteen patients to the non-counseling group. There was a significant decrease in weight, BMI, fat mass, and KOQOL (P<0.05) with improvements in total cholesterol, low-density lipoprotein, and triglycerides. The counseling group had a greater reduction in body weight, BMI, body fat, and fat mass compared to the non-counseling group, although it was not significant. In the BMI below 35 (n=25), the reduction ratio of body weight, body fat mass, and body fat was higher in the counseling group than in the non-counseling group; additionally, body fat decreased significantly in counseling group (P<0.05). No severe adverse effects were observed. Conclusion: KM treatment could be effective for weight loss, especially in patients with morbid obesity, KM counseling could also be a good tool for weight loss, typically in patients with BMI<35 kg/m2.

Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial

Kyung-Min Shin,박지은,육태한,김종욱,Ojin Kwon,최선미 한국한의학연구원 2019 Integrative Medicine Research Vol.8 No.1

Background: Prehypertension and hypertension are associated with cardiovascular disease, ischemic heart disease, and stroke morbidity. The purpose of this study is to evaluate the effectiveness and safety of moxibustion in patients with prehypertension or hypertension. Methods: Forty-five subjects with prehypertension or stage I hypertension were randomized into three groups: moxibustion treatment group A (2 sessions/week for 4 weeks), moxibustion treatment group B (3 sessions/week for 4 weeks), and control group (nontreated group). The primary outcome measure was the change in blood pressure after 4 weeks of treatment. Safety was assessed at every visit. Results: There were no significant differences in systolic blood pressure (SBP) or diastolic blood pressure (DBP) among three groups after 4 weeks of treatment (p = 0.4798 and p = 0.3252, respectively). In treatment group B, there was a significant decrease in SBP and DBP from baseline to 4 weeks of treatment (mean difference (MD) −9.55; p = 0.0225, MD −7.55; p = 0.0098, respectively). There were no significant differences among groups in secondary outcome measures after 4 weeks of treatment. Six adverse events (AEs) in the treatment group A and 12 AEs in the treatment group B occurred related to the moxibustion treatment. Conclusion: In conclusion, the results of this study show that moxibustion (3 sessions/week for 4 weeks) might lower blood pressure in patients with prehypertension or stage I hypertension and treatment frequency might affect effectiveness of moxibustion in BP regulation. Further randomized controlled trials with a large sample size on prehypertension and hypertension should be conducted. Trial registration: This study was registered with the ‘Clinical Research Information Service (CRIS)’, Republic of Korea (KCT0000469), and the protocol for this study was presented orally at the 15th International Council of Medical Acupuncture and Related Techniques (ICMART) in Athens, 25–27 May 2012.

암 환자 대상 설문지, 맥진기, 설진기 결과를 활용한 한열허실변증에 대한 예비 연구

최유진(Yujin Choi),김수담(Soo-Dam Kim),권오진(Ojin Kwon),박효주(Hyo-Ju Park),김지혜(JiHye Kim),최우수(Woosu Choi),고명현(Myung-Hyun Ko),하수정(Su-Jeung Ha),송시연(Si-Yeon Song),박소정(So-Jung Park),유화승(Hwa-Seung Yoo),정미경(Mi-Kyung 대한한의학회 2021 대한한의학회지 Vol.42 No.1

Effects of herbal medicine (Danggwijagyaksan) for treating climacteric syndrome with a blood-deficiency-dominant pattern: A randomized, double-blind, placebo-controlled pilot trial

박은지,Seon-Eun Baek,김미경,Ae-Ran Kim,Hyo-ju Park,Ojin Kwon,이준환,유정은 한국한의학연구원 2021 Integrative Medicine Research Vol.10 No.3

Background: Danggwijagyaksan (DJS) has been one of the most widely used herbal medicines for gynecological disorders in traditional East Asian medicine. Several clinical studies about DJS have shown improvement in menopausal symptoms. This pilot study aimed to evaluate the efficacy, safety and feasibility of DJS for treating climacteric syndrome with a blood-deficiency-dominant pattern. Methods: This was a randomized, double-blind, placebo-controlled pilot trial. A group of 45-to 60-year-old women with climacteric syndrome were registered for the trial. The participants received treatment over a 4-week period and were then followed for 4 weeks. The primary outcome measure was the mean change in the Menopause Rating Scale (MRS). Secondary outcome measures included the World Health Organization Quality of Life-BREF (WHOQOL-BREF), the Blood-Deficiency Scoring System (BDSS), lean body mass, and serum hormone levels, including follicle-stimulating hormone (FSH) and estradiol (E2) levels. Results: The MRS and BDSS scores decreased significantly in both groups, but the differences between two groups were not significant. The WHOQOL-BREF scores increased in the control group. No statistically meaningful differences in serum hormone levels or lean body mass were observed in both groups. There were no serious adverse events, and the laboratory tests were within the normal range. The recruitment rate, completion rate and medication adherence rate were over 90% in both groups, indicating high feasibility. Conclusions: DJS showed clinical effectiveness in the treatment of climacteric syndrome with a blood-deficiency-dominant pattern. Additionally, DJS was shown to be safe and feasible for a large-scale study to confirm the efficacy of the treatment. Trial registration: Clinical Research Information Service (CRIS, https://cris.nih.go.kr): KCT0002387.

Socheongryong-tang for improving nasal symptoms associated with allergic rhinitis : A study protocol for a randomized, open-label, cetirizine controlled, clinical trial

Kim, Young-Eun,Son, Mi Ju,Jung, So Young,Kwon, Ojin,Lee, Jun-Hwan,Lee, Dong-Hyo Williams & Wilkins Co 2018 Medicine Vol.97 No.34

<P><B>Abstract</B></P><P><B>Introduction:</B></P><P>Socheongryong-tang (SCRT) is an herbal medicine with anti-inflammatory and anti-allergic properties, commonly used in East Asian countries to reduce rhinitis symptoms. There have been several clinical studies of its effects on allergic rhinitis (AR), but no trials comparing it with conventional treatment. We present the protocol for a feasibility trial to assess the safety and clinical effectiveness of SCRT in AR in comparison with cetirizine.</P><P><B>Methods and analysis:</B></P><P>This is a randomized, open-label, cetirizine-controlled clinical trial. A total of 30 AR patients who have signed informed consent forms will be recruited and randomly assigned to SCRT or cetirizine groups at a 1:1 ratio. The participants will visit the clinical research center every week and receive SCRT granules or cetirizine tablets. SCRT will be taken twice daily, cetirizine will be taken once daily, and treatment medication will be taken for 2 weeks. Data will be collected at baseline, at week 2, and at week 4 after random allocation. The primary outcome will be the mean change in the total nasal symptom score from baseline to week 2. Secondary outcome measures will include the mini Rhinoconjunctivitis Quality of Life Questionnaire and total serum immunoglobulin E. To assess the safety of SCRT, a liver and renal function test will be conducted before and after treatment, and the participants will be asked about any occurrence of adverse events at every visit. The recruitment rate, completion rate, and medication adherence will also be calculated to assess feasibility.</P><P><B>Discussion:</B></P><P>The findings of this study are expected to provide the basis for a full-scale randomized controlled trial to confirm the safety and effectiveness of SCRT for the treatment of nasal symptoms in patients with AR patients not controlled by conventional therapy.</P><P><B>Trial registration:</B></P><P>This study has been registered at the Korean National Clinical Trial Registry, Clinical Research Information Service (KCT0002380).</P>

Acupuncture for dry eye syndrome after refractive surgery: A randomized controlled pilot trial

Jun-Hwan Lee,Kyungsun Han,김태훈,Ae-Ran Kim,Ojin Kwon,Joo-Hee Kim,Jeong-Eun Kim,이상훈,신미숙,So-Young Jung,Hyo-ju Park,Sanghun Lee 한국한의학연구원 2021 Integrative Medicine Research Vol.10 No.1

Background: Dry eye syndrome is the most common complication of refractive surgery. Acupuncture is widely used for the treatment of ophthalmologic diseases, but to date, few have explored the effects of acupuncture for the treatment of this condition following refractive surgery. The objective of this study is to assess the feasibility of a study design for evaluating the effectiveness of acupuncture treatment along with usual care compared with usual care only for dry eye syndrome after refractive surgery. Methods: A total of 18 patients with dry eye syndrome occurring after refractive surgery participated in this study. For 4 weeks, the acupuncture plus usual care and usual care only groups received treatment three times a week. A series of assessments, namely the ocular surface disease index (OSDI), visual analog scale for ocular discomfort, quality of life, tear film break-up time, Schirmer 1 test, and fluorescein-stained corneal-surface photography, along with other general assessments were carried out. Results: Although preliminary, changes in OSDI from the baseline values were significantly different between the two groups at week 5 (p = 0.0003). There was a significant difference in the trends of OSDI changes between the acupuncture plus usual care and the usual care only groups (p = 0.0039). No serious adverse events were reported during the study. Conclusion: Four weeks of acupuncture treatment in addition to usual care is a feasible treatment for dry eye syndrome after refractive surgery. A full-scale randomized controlled trial is needed to confirm the clinical effectiveness of acupuncture.